Researchers develop 3D printed ingestible pill4 Aug 2019
Represents the first non-invasive diagnostic tool capable of providing a profile of microbiome populations throughout the entire GI tract.
A research team led by Tufts University engineers has developed a 3D printed ingestible pill that samples bacteria found in the gut - known as the microbiome - as it passes through the gastrointestinal tract (GI). The ability to profile bacterial species inhabiting the gut could have important implications for the understanding of conditions that affect and are affected by the intestinal microbiome, according to the researchers.
The 3D printed pill described in the journal Advanced Intelligent Systems represents the first non-invasive diagnostic tool capable of providing a profile of microbiome populations throughout the entire GI tract, according to the researchers. Current methods of sampling the microbiome involve primarily the analysis of fecal DNA and metabolites, but that approach provides little information of the environment upstream of the distal colon, where bacterial species can vary significantly.
The pill has been studied extensively in vitro and in vivo and found to provide accurate identification of bacterial populations and their relative abundance, the paper says. It has been tested in pigs and primates, yet clinical trials will be needed to determine if the pill can be used routinely in humans for clinical care.
More than 1,000 species of bacteria inhabit the healthy gut. The vast majority of these bacteria have a beneficial, supportive role in digestion and protection against disease. When the natural balance of the microbiome is disturbed, a condition called “dysbiosis” occurs, which can be associated with inflammation, susceptibility to infections, and even the exacerbation of other diseases such as cancer. Research is increasingly unveiling specific microbiome metabolites that have beneficial or protective effects against disease.
“We are learning quite a lot about the role of gut microbiome in health and disease. However, we know very little about its biogeography,” said Sameer Sonkusale, professor of electrical and computer engineering at Tufts University’s School of Engineering and corresponding author of the study. “The pill will improve our understanding of the role of spatial distribution in the microbiome profile to advance novel treatments and therapies for a number of diseases and conditions.”
The pill is more sophisticated than just a sponge. It is manufactured in a 3D printer with microfluidic channels that can sample different stages of the GI tract. The surface of the pill is covered with a pH-sensitive coating so that it does not absorb any samples until it enters the small intestine (bypassing the stomach) where the coating dissolves. A semi-permeable membrane separates two chambers in the pill – one containing helical channels that take up the bacteria and the other containing a calcium salt-filled chamber. The salt chamber helps create an osmotic flow across the membrane which pulls the bacteria into the helical channels. A small magnet in the pill enables one to hold it at certain locations in the gut for more spatially targeted sampling using a magnet outside the body. A fluorescent dye in the salt chamber helps locate the pill after it exits the GI tract.
“The design of this device makes it incredibly easy to use, posing little risk to the subject, yet providing so much information,” said Giovanni Widmer, professor of infectious disease and global health at Cummings School of Veterinary Medicine at Tufts University, and co-author of the study responsible for testing the pill's effectiveness in animals and for high throughput sequencing the microbiome samples.
The researchers see this technology as bridging an important gap in understanding the complexity of the ecosystem of the gut. “We have advanced technologies to analyze bacterial populations using DNA sequencing, but until now have not had a way to sample bacteria throughout the GI tract in a way that is not invasive,” said Hojatollah Rezaei Nejad, a post-doctoral fellow studying novel applications of 3D printing in Sonkusale’s laboratory at Tufts and lead author of the study. “By sampling non-invasively, this pill could help us better identify and understand the role of different intestinal bacterial species in health and disease.”
New HQ for developer of world's first fully automated drug discovery platform
8 Jan 2020
End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.Read more
NIH researchers discover new autoinflammatory disease
3 Jan 2020
Mutations in the RIPK1 gene responsible for CRIA syndrome.Read more
BioAscent scientists help identify potential new treatments for cancer
30 Dec 2019
Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.Read more
NIH launches first US clinical trial of patient-derived stem cell therapy to replace dying cells in retina
13 Dec 2019
NEI-led study to test safety of treatment for a form of age-related macular degeneration that currently lacks treatment.Read more
Sanofi bolsters its immuno-oncology pipeline for $2.5B
6 Dec 2019
Lead asset THOR-707 being explored across multiple solid tumor types alone and in combination with immune checkpoint inhibitors and other future IO combinations.Read more
Catalent to partner with Ethicann on new fast-dissolve cannabinoid-based treatment
4 Dec 2019
Program will initially focus on using Catalent’s orally disintegrating tablet technology to develop a combination pharmaceutical-grade CBD and THC product that, if approved, would treat patients suffering from MS spasticity.Read more
Eli Lilly unveils shared innovation laboratory in San Francisco
3 Dec 2019
Lilly Gateway Labs will provide biotech companies direct access to Lilly scientists and expertise.Read more
Ground-breaking work creates novel oil-in-water nanoemulsions
3 Dec 2019
New innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives.Read more
UK experiences a 'baby boom' of new life sciences ventures
2 Dec 2019
Unprecedented levels of investment cited as a major force driving the expansion.Read more
Recipharm joins the AMR Industry Alliance
15 Nov 2019
Marks the latest step in the company’s ongoing efforts to engage with other organisations working to tackle antimicrobial resistance.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation